Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | Milan | Healthcare | Pharmaceuticals | €686.15B | 73.7x | 0.7 | €761.60 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson | Milan | Healthcare | Pharmaceuticals | €325.55B | 17x | -0.42 | €136 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbvie | Milan | Healthcare | Pharmaceuticals | €288.70B | 76.2x | -5.94 | €162.60 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Milan | Healthcare | Pharmaceuticals | €132.55B | 36.7x | -0.92 | €246.70 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Milan | Healthcare | Pharmaceuticals | €114.41B | 16.1x | 0.05 | €20.14 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Milan | Healthcare | Pharmaceuticals | €113.46B | 271.2x | -2.96 | €91.57 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Milan | Healthcare | Pharmaceuticals | €113.25B | 18.3x | 6.87 | €92.99 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vertex Pharmaceuticals | Milan | Healthcare | Pharmaceuticals | €111.21B | -235.9x | 2.04 | €430.85 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb | Milan | Healthcare | Pharmaceuticals | €85.15B | 17.7x | 0.05 | €42.14 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zoetis | Milan | Healthcare | Pharmaceuticals | €59.68B | 27.7x | 3.37 | €134.16 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Milan | Healthcare | Pharmaceuticals | €52.86B | 19x | -11.53 | €121 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer | Milan | Healthcare | Pharmaceuticals | €22.66B | -8.9x | -0.62 | €23 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen | Milan | Healthcare | Pharmaceuticals | €15.24B | 10.6x | 0.26 | €104.20 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomarin Pharmaceutical | Milan | Healthcare | Pharmaceuticals | €10.57B | 27.8x | 0.17 | €55.16 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Recordati | Milan | Healthcare | Pharmaceuticals | €10.24B | 24.5x | 3.4 | €49.46 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.1% Upside | Upgrade to Pro+ | |
Incyte | Milan | Healthcare | Pharmaceuticals | €9.96B | 366.4x | -3.65 | €51.32 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viatris | Milan | Healthcare | Pharmaceuticals | €8.42B | -15.1x | 0.01 | €7.12 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion Oyj | Milan | Healthcare | Pharmaceuticals | €7.64B | 22x | 0.4 | €51.90 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Organon | Milan | Healthcare | Pharmaceuticals | €2.76B | 3.6x | -0.2 | €10.25 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pharmanutra | Milan | Healthcare | Pharmaceuticals | €496.49M | 29.9x | 0.98 | €51.70 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Laboratorio Farmaceutico Erfo | Milan | Healthcare | Pharmaceuticals | €9.01M | 25.9x | €1.09 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40% Upside | Upgrade to Pro+ |